U.S Ambulatory Infusion Centers Market

U.S. Ambulatory Infusion Centers Market Outlook

• The U.S ambulatory infusion centers market was valued at US$ 8.9 Bn in 2024
• The U.S. ambulatory infusion centers industry is projected to grow at a CAGR of 8.8% from 2025 to 2035 and reach US$ 22.5 Bn by the end of 2035

Analysts’ Viewpoint regarding the U.S. Ambulatory Infusion Centers Market

The U.S. ambulatory infusion centers market is expected to grow at a faster pace during the forecast period, mainly due to a greater demand for cost-effective and patient-centered care options. Ambulatory infusion centers service patients in an outpatient setting for intravenous therapies, providing a more convenient service where the patient does not have to be treated in a hospital setting.

The growth of the U.S. ambulatory infusion center sector is primarily due to the increasing incidence of chronic illnesses (e.g. cancer, autoimmune disease, cardiovascular diseases) that require multiple times of infusion therapy in a particular time period. Also, the increased availability of biologics and specialty medications has led to more treatment options for patients, and thus the need for an infusion service.

In addition, public policies and government initiatives are shaping the sector. For example, in March 2023, the U.S. Department of Veterans Affairs (VA) started the "Close to Me Novel Infusion Care Delivery" program to facilitate residents’ access to services.

The mission of this program is to reduce the distance and time the patient spends traveling by expanding infusion services at the closest location for the patient. Furthermore, the transition from volume- to value-based care will facilitate the future growth of infusion centers as value-based care providers have lower costs, higher patient outcomes, and less hospital admissions through having an outpatient infusion service.

U.S. Ambulatory Infusion Centers Market Introduction

The U.S. ambulatory infusion centers industry is moving fast as healthcare providers search for effective, patient-friendly alternatives to hospital-based infusion therapy. Ambulatory infusion centers can provide outpatient intravenous treatments, granting patients access to the necessary medications in a comfortable, specialized environment, like in a hospital, without the hospital stay.

They are supported by a growing U.S. ambulatory infusion centers market due to increasingly prevalent biologic therapies with precise administration and monitoring. Ambulatory infusion centers are a lower-cost option than the hospital for patients needing regular infusions and they provide a higher quality of care with most patients receiving the medication and providing a hospital of specialized expertise.

Ambulatory infusion centers are becoming the preferred option for both - patients needing the treatment and the healthcare providers, as they are more convenient and accessible alternatives. Technology advancements are also changing the U.S. ambulatory infusion centers market.

For example, infusion pumps and remote monitoring and personalized medicine, just to name a few, have all improved the efficiency of treatment coupled with growing attention to the removal of application of big data analytics and artificial intelligence solutions by health providers to manage infusion protocols and limit adverse reactions to treatment in patients.

Many mobile infusion centers are expanding service offerings to include specialty treatments for patients struggling with neurological disorders, autoimmune diseases, and rare genetic conditions.

Cost Efficiency and Favorable Reimbursement Models Anticipated to Drive the U.S. Ambulatory Infusion Centers Market Size

Ambulatory infusion centers (AICs) are cost-effective as compared to hospital infusion services. AICs pair high-quality care in a lower-cost setting to relieve financial costs to both - the healthcare provider and the patient. This cost-effectiveness is one of the more powerful drivers of the U.S. ambulatory infusion centers market growth, especially as the U.S. healthcare system has moved toward value-based care and cost containment initiatives.

For instance, a study published in the American Journal of Managed Care has found that patients receiving biologics at an AIC had total healthcare costs that were 30% lower than outpatients receiving treatment at a hospital outpatient department. The same article reported that the average cost of an infusion administered at an ambulatory center was US$ 1,000 – US$ 1,500 less than in a hospital setting.

The reimbursement landscape is also favorable to AICs. The Centers for Medicare & Medicaid Services (CMS) has introduced reimbursement models to a greater extent that promote site-neutral payments such that the provider will receive the same payments for the same services independent of site condition. More specifically, there are payment models that favor provider-based billing at independent infusion centers through advances in Medicare Part B reimbursement, which will improve the revenue cycle for infusion centers.

CMS is not the only payer interacting in new ways to control costs through enhanced access to effective care in ambulatory settings; many commercial payers have developed site-of-care optimization policies that encourage treatment in cost-efficient care such as AICs to limit specialty drug expenditure.

Similarly, many commercial payers continue to develop bundled payments or per-visit reimbursement strategies that enhance the ability of infusion centers to be financially viable for infusion therapies. The convergence of these economic incentives and administrators within payers to enhance care delivery and satisfaction, to develop patient-centered care environments, as well as the evolution of patient satisfaction and preferences for care to be delivered in the outpatient, or non-hospital, setting continue to make AICs a foundational part of efficient chronic care delivery systems in the United States.

Technological Advancement in Clinics Bolstering the U.S. Ambulatory Infusion Centers Market Expansion

Practice improvement in infusion therapies, drug formulations, and patient monitoring has enhanced the appeal, safety, and effectiveness of ambulatory infusion centers. The integration of technology is paramount in ensuring medication outcomes by improving accurate dosing and monitoring use of electronic health records (EHR), telemonitoring, and smart infusion pump technology which has enabled infusion therapies to effectively manage updated utility and reduce the risk from potential patient harm.

For example, the primitive smart infusion pumps will now automatically alarm for certain adverse conditions including infiltration and air bubble detection in the IV line, which alerts staff and improves patient safety. These smart infusion pumps integrate with EHR platforms and allow for documentation and dosage adjustment to be completed with automated, immediate update based on changes in the individual patient's clinical profile and laboratory results.

The availability of new subcutaneous and extended-release formulations have made it possible for all treatments once limited to hospitals, to now be infused safely and effectively in the home or formal outpatient locations. This new approach is broadening the array of conditions treated in ambulatory infusion centers.

The FDA-approved Ocrevus (ocrelizumab), a monoclonal antibody for patients with multiple sclerosis, now has the potential to be infused in their homes or in an ambulatory setting due to decreased frequency of dosing and its favorable safety profile. Biologics have also shifted to outpatient infusion centers, including Remicade (infliximab) and Stelara (ustekinumab) because of the availability of pre-infusion screening and prediction methods using Artificial Intelligence (AI) related to adverse reactions to infusion therapy.

Moreover, wearable biosensors and remote patient monitoring resources have improved post-infusion monitoring and surveillance as it pertains to delayed allergic reactions or treatments.

Hospital-based infusion centers segment dominating Disease Specialties Segment of the U.S Ambulatory Infusion Centers Market

Hospital-based infusion centers have stayed at the top as they are designed for comprehensive care, have the infrastructure to take on complex care, and are accessible via transportation. They offer specialized medical staff, equipment for infusion, and emergency support that are preferable for patients undergoing critical intravenous therapies.

In addition, providing care in hospitals also allows for integrated services of care as multiple teams could provide multidisciplinary care with just one series of appointments, particularly for patients with chronic illnesses or patients experiencing oncology treatment. Many insurance and reimbursement policies also reinforce the business model for hospital-based infusion centers over standalone ambulatory infusion centers.

Many of these insurers bundle the infusion therapy costs with other hospital services for an in-network patient visit to the hospital, making it financially feasible for patients to receive infusion therapy in hospitals. Many hospitals have strong agreements/partnerships with pharmaceutical companies that supply only the most recent infusion therapy drugs, and they are a consistently reliable source of those drugs while it is more difficult to find drugs for ambulatory infusion centers.

Access to contract drugs provides a competitive advantage for hospital-based infusion centers and this is an advantage they use to limit competition and to stay at the top of their market.

Analysis of Key Players in the U.S. Ambulatory Infusion Centers Market

Key players operating in the U.S ambulatory infusion centers market are investing in various technologies such as 3D printing and CAD/CAM in order to design and manufacture dental restorations to unrivaled standards of precision and personalization. Moreover, they are working on developing restorative procedures such as digital orthodontics in order to drive greater productivity and patient outcomes.

Flexcare Infusion Centers, Thrivewell, Hy-Vee Health, Agile Infusion Services LLC, Infusion Solutions, IVXpress, Inc., Infusion for Health, Cedars-Sinai, Arnot Health, PharmaScript, Naval Medical Center Portsmouth, Valley Health Systems, Cheyenne Regional Medical Center, Pacific Medical Centers, ChristianaCare, and Others are some of the leading key players operating in the U.S ambulatory infusion centers industry.

Each of these players has been profiled in the U.S. ambulatory infusion centers market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Key Developments in the U.S. Ambulatory Infusion Centers Market

• In January 2025, Optum, a subsidiary of UnitedHealth Group and the parent company of the ambulatory surgery center (ASC) chain SCA Health, did announce its agreement to acquire FlexCare Infusion. FlexCare Infusion is an ambulatory infusion network having its HQ in Oklahoma City. This acquisition signals Optum's strategic expansion into the growing market for outpatient infusion services, thereby complementing SCA Health's existing network of surgical facilities.
• In April 2024, Hy-Vee, Inc. opened its first infusion clinic in West Des Moines, Iowa, offering treatments for chronic conditions. The clinic, staffed by licensed physicians and nurse practitioners, features five group suites and three private rooms.

U.S. Ambulatory Infusion Centers Market Snapshot